Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MITF | O75030 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TAS2R46 | P59540 | 10/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.31 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741385 | 0.99 | KMT2A (0.39) | KMT2AMEN1MITFPOLBTAS2R46 | |
| SCHEMBL6741726 | 0.91 | KMT2A (0.41) | KMT2AMEN1MITFPOLBTAS2R46 | |
| SCHEMBL6739764 | 0.91 | TAS2R46 (0.37) | KMT2AMEN1MITFPOLBTAS2R46 | |
| SCHEMBL6742416 | 0.82 | TAS2R46 (0.36) | KMT2AMEN1MITFTAS2R46TAS2R31 | |
| SCHEMBL6741650 | 0.81 | TAS2R46 (0.41) | KMT2AMEN1TAS2R46RECQLTDP1 | |
| SCHEMBL6744280 | 0.78 | TAS2R46 (0.39) | KMT2AMEN1TAS2R46RECQLTDP1 | |
| SCHEMBL6739772 | 0.76 | TAS2R46 (0.39) | TAS2R46TAS2R31TAS2R10 | |
| SCHEMBL6741361 | 0.72 | PKM (0.52) | KMT2AMEN1MITFPOLBPKM | |
| SCHEMBL6745287 | 0.72 | PKM (0.52) | KMT2AMEN1MITFPOLBPKM | |
| SCHEMBL6745280 | 0.72 | PKM (0.52) | KMT2AMEN1MITFPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229936-A1 | Treatment of hepatitis C virus infection with sesquiterpene lactones | HSIEH HSING-PANG (TW) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229936-A1 | Treatment of hepatitis C virus infection with sesquiterpene lactones | HAVCR2, HCCS, ZC3HAV1 | KMT2A 4010/4885MEN1 4189/4885MITF 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.